Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) announced that its strategic partner, Lishman Global Inc., has formally submitted the company's VMS+ 4.0 system to China's National Medical Products Administration (NMPA) for regulatory approval. Importantly, Lishman Global has qualified for the NMPA's "green channel" pathway, an expedited review process designed to accelerate approval of innovative medical technologies addressing significant clinical needs. This designation is expected to streamline the regulatory timeline and facilitate faster access to the Chinese market.
China represents a substantial and rapidly growing opportunity in cardiology. Cardiovascular disease remains the leading cause of mortality in the country, with an estimated 330 million patients affected. Echocardiography is the most widely used cardiac imaging modality in China due to its cost-effectiveness, portability, and scalability across urban and rural healthcare settings. However, variability in image interpretation and limited access to advanced imaging modalities such as MRI have created a strong need for AI-driven tools that can improve diagnostic accuracy and workflow efficiency.
Ventripoint's VMS+ 4.0 addresses this need by providing MRI-equivalent volumetric measurements using standard 2D echocardiography. Powered by the company's proprietary Knowledge Based Reconstruction technology, the platform enables clinicians to assess all four chambers of the heart with high accuracy, supporting diagnosis and management of conditions such as congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.
"We are excited to take this important step toward bringing VMS+ 4.0 to the Chinese market," said Paul Gibson, Chief Technology Officer of Lishman Global Inc. "Qualification for the NMPA's green channel underscores the clinical relevance and innovation of VMS+ 4.0 and provides a clear pathway to accelerated adoption. China's scale, combined with its increasing focus on improving cardiovascular outcomes, makes it an ideal environment for this technology."
Hugh MacNaught, President and Chief Executive Officer of Ventripoint Diagnostics, added: "Hitting this regulatory milestone with Lishman Global is a key validation of both our technology and our international strategy. China is one of the most important cardiac care markets in the world. With the benefit of an expedited review pathway, we are well positioned to bring VMS+ 4.0 to clinicians and patients more quickly. By enabling more accurate and reproducible cardiac measurements using existing ultrasound infrastructure, VMS+ has the potential to significantly expand access to high-quality cardiac care."
The company will provide further updates as the regulatory review process progresses. This submission marks a significant milestone in Ventripoint's global expansion strategy and reflects growing demand for advanced, accessible cardiac imaging solutions in one of the world's largest healthcare markets.
